Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared on LinkedIn:
“Kicking off 2026: A New Perspective on Avatrombopag in Aplastic Anemia
I am pleased to start the new year by sharing our latest review article, published in Therapeutic Advances in Hematology.
While Thrombopoietin Receptor Agonists (TPO-RAs) like Eltrombopag have revolutionized the treatment of Aplastic Anemia (AA), hepatotoxicity and dietary restrictions remain significant challenges for many patients.
Our team conducted a comprehensive review of clinical evidence from 2023 to 2025 to evaluate the efficacy and safety of Avatrombopag (AVA) as an alternative.
Key Findings for Clinical Practice:
- High Efficacy: Across the reviewed studies, we observed Overall Response Rates (ORR) ranging from 55% to 85%, with complete response rates reaching up to one-third of treated patients.
- Superior Liver Safety: Unlike earlier agents in this class, Avatrombopag demonstrated a favorable safety profile with no clinically relevant hepatotoxicity reported. It appears safe even for patients with underlying liver dysfunction.
- Rapid Response: Hematologic improvement typically occurred within 1–2 months, aligning well with clinical decision-making timelines.
- Patient Convenience: AVA requires no dietary restrictions and does not undergo significant hepatic metabolism, simplifying management for complex patients.
Title: Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence
I extend my sincere gratitude to Dr. Mostafa Faisal Mohammed Saleh, Dr. Ahmed Kotb Abdrabou, Dr. Alfadil Haroon, Dr. Hadeel Samarkandi, Dr. Hazza Alzahrani, Dr. Mahmoud Aljurf, Dr. Ali Alahmari.
Read the full review here.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 09:31Help Shape the New ASH Iron Deficiency Guidelines – American Society of Hematology
-
Oct 10, 2026, 09:05Wolfgang Miesbach: Moving from Bleed Control to Comprehensive Joint Health
-
Oct 10, 2026, 07:59Leila Caroline Souza Reis: Enoxaparin Dosing for VTE Prevention in Adults With Obesity
-
Oct 10, 2026, 07:41Adeeb Bazuhair: New Evidence for Catheter Directed Thrombolysis in Acute PE
-
Oct 10, 2026, 07:22Poppy Clarke: Turning Steps Into Support for Thrombosis Awareness
-
Oct 10, 2026, 07:12Hamzah Khan: The Role of Genuine Curiosity in Driving High-Impact Academic Research
-
Oct 10, 2026, 06:58Nita Radhakrishnan: Turning Evidence Into Action for Hemophilia Care in India
-
Oct 10, 2026, 06:48Nutan Kaushik: HemeNext 2.0 Brings Global Perspectives to Hematology
-
Oct 10, 2026, 06:43Suthesh Sivapalaratnam: Advancing Bleeding Disorder Care at EHC 2026